# EDGAR Filing Document

**Accession Number:** 0001729427
**File Stem:** 0001683168-26-001368
**Filing Date:** 2026-2
**Character Count:** 21583
**Document Hash:** 0d0a7552383e89d0a0bfe4d09f537ac5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-001368.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001683168-26-001368

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**EFFECTIVENESS DATE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CNS Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001729427
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822318545
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293895
- **FILM NUMBER:** 26701940

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 WEST LOOP SOUTH
- **STREET 2:** SUITE 900
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77027
- **BUSINESS PHONE:** 1-800-946-9185

**MAIL ADDRESS:**
- **STREET 1:** 2100 WEST LOOP SOUTH
- **STREET 2:** SUITE 900
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77027

As filed with the Securities and Exchange Commission on February 27, 2026

Registration No. 333-

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**CNS Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **82-2318545** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |

---

---

| | |
|:---|:---|
| **2100 West Loop South, Suite 900**<br>**Houston, Texas** | **77027** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**CNS Pharmaceuticals, Inc. 2020 Equity Plan (Amended and Restated)**

(Full title of the plans)

**Rami Levin**

**Chief Executive Officer**

**2100 West Loop South, Suite 900**

**Houston, Texas 77027**

**(800) 946-9185**

(Name and address of agent for service)

Copies to:

**Cavas S. Pavri, Esq.**

**Johnathan C. Duncan, Esq.**

**ArentFox Schiff LLP**

**1717 K Street, NW**

**Washington, DC 20006**

**(202) 724-6847**

**Facsimile: (202) 778-6460**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by CNS Pharmaceuticals, Inc. (the "Registrant"), to register an additional 115,032 shares (the "Additional Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), that may be issued pursuant to the CNS Pharmaceuticals, Inc. 2020 Equity Plan, as amended and restated (the "2020 Plan").

The Additional Shares are an incremental increase to the number of shares of Common Stock previously registered for issuance under the 2020 Plan pursuant to the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on November 22, 2023 (file no. 333-275699) and July 22, 2020 (file no. 333-239998) (collectively, the "Prior Registration Statements"). This Registration Statement relates to securities of the same class as that to which each of the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements, except to the extent supplemented or amended or superseded by the information set forth or incorporated herein.

The shares of Common Stock registered by the foregoing Registration Statements on Form S-8 have been adjusted to give effect to, in each case as appropriate, (i) the Registrant's 1-for-50 reverse stock split of the issued and outstanding shares of Common Stock effective as of June 4, 2024, (ii) the Registrant's 1-for-50 reverse stock split of the issued and outstanding shares of Common Stock effective as of February 21, 2025, and (iii) the Registrant's 1-for-12 reverse stock split of the issued and outstanding shares of Common Stock effective as of July 22, 2025.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm) and any amendments on [Form 10-K/A](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002998/cns_10ka1-123124.htm) for the year ended December 31, 2024 (filed on March 31, 2025, and April 30, 2025);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Quarterly Reports on Form 10-Q for the quarter ended [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825003733/cns_i10q-033125.htm) (filed on May 15, 2025), for the quarter ended [June 30, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825006162/cns_i10q-063025.htm) (filed on August 14, 2025), and for the quarter ended [September 30, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825008466/cns_i10q-093025.htm) (filed on November 14, 2025);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Registrant's Current Reports on Form 8-K and any amendments on Form 8-K/A filed on: [January 3, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825000077/cns_8k.htm) (other than Item 7.01 thereof), [February 21, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001174/cns_8k.htm), [March 20, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm), [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/cns_8k.htm), [May 15, 202](https://www.sec.gov/Archives/edgar/data/1729427/000168316825003575/cns_8k.htm)5, [July 22, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/cns_8k.htm), [November 21, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825008624/cns_8k.htm), [December 17, 2025](https://www.sec.gov/Archives/edgar/data/1729427/000168316825009208/cns_8k.htm), and [February 17, 2026](https://www.sec.gov/Archives/edgar/data/1729427/000168316826001066/cns_8k.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Registrant's Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1729427/000168316825007760/cns_def14a.htm) filed on October 24, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The description of our common stock, par value $0.001 per share contained in our Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1729427/000168316819003435/cns_8a12b-11052019.htm), dated and filed with the SEC on November 5, 2019, and any amendment or report filed with the SEC for the purpose of updating the description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, subsequent to the date hereof and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall also be deemed to be incorporated by reference herein and to be a part hereof from the dates of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.**

The following exhibits are filed as a part of or incorporated by reference into this Registration Statement:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | &nbsp;&nbsp;&nbsp;**<u>Description of Exhibit</u>** |
| 4.1 | &nbsp;&nbsp;&nbsp;[Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1729427/000168316818001028/filename3.htm) (incorporated by reference to Exhibit 2.1 to the Form 1-A, as amended (file no. 024-10855), filed with the Commission on June 15, 2018) |
| 4.2 | &nbsp;&nbsp;&nbsp;[Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada](https://www.sec.gov/Archives/edgar/data/1729427/000168316822008064/cns_ex0301.htm) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on November 28, 2022) |
| 4.3 | &nbsp;&nbsp;&nbsp;[Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada](https://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/cns_0301.htm) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on May 3, 2024) |
| 4.4 | &nbsp;&nbsp;&nbsp;[Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada](https://www.sec.gov/Archives/edgar/data/1729427/000168316824003998/cns_ex0301.htm) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on June 5, 2024) |
| 4.5 | &nbsp;&nbsp;&nbsp;[Certificate of Change filed with the State of Nevada](https://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/cns_0301.htm) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on June 5, 2024) |
| 4.6 | &nbsp;&nbsp;&nbsp;[Certificate of Change filed with the State of Nevad](https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/cns_ex0301.htm)a (incorporated by reference to Exhibit 3.1 of the Form 8-K filed July 22, 2025) |
| 4.7 | &nbsp;&nbsp;&nbsp;[Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada](https://www.sec.gov/Archives/edgar/data/1729427/000168316825008624/cns_ex0301.htm) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on November 21, 2025) |
| 4.8 | &nbsp;&nbsp;&nbsp;[Amended and Restated Bylaws of CNS Pharmaceuticals, Inc](https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/cns_ex0301.htm). (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on August 15, 2023) |
| 4.9 | &nbsp;&nbsp;&nbsp;[CNS Pharmaceuticals, Inc. 2020 Equity Plan](https://www.sec.gov/Archives/edgar/data/1729427/000168316825008624/cns_ex1001.htm) (as amended and restated on November 17, 2025) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on November 21, 2025) |
| 5.1# | &nbsp;&nbsp;&nbsp;[Opinion of ArentFox Schiff LLP](cns_ex0501.htm) |
| 23.1# | &nbsp;&nbsp;&nbsp;[Consent of MaloneBailey, LLP](cns_ex2301.htm) |
| 23.2# | &nbsp;&nbsp;&nbsp;Consent of ArentFox Schiff LLP (included in [Exhibit 5.1](cns_ex0501.htm)) |
| 24.1 | &nbsp;&nbsp;&nbsp;[Power of Attorney](#s8_poa) (included in the signature pages of this Registration Statement) |
| 107# | &nbsp;&nbsp;&nbsp;[Filing Fee Table](cns_ex107.htm) |

---

# Filed herewith.

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Houston, Texas, on February 27, 2026.

---

| | |
|:---|:---|
| **CNS PHARMACEUTICALS, INC.** | **CNS PHARMACEUTICALS, INC.** |
| By: | /s/ Rami Levin |
|  | Rami Levin |
|  | Chief Executive Officer, President and Director |

---

**POWER OF ATTORNEY**

KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Rami Levin and Christopher Downs, or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and ratifying and confirming all that such attorney-in-fact and agent or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Rami Levin | Chief Executive Officer, President and Director | February 27, 2026 |
| Rami Levin | (Principal Executive Officer) |  |
| /s/ Christopher Downs | Chief Financial Officer | February 27, 2026 |
| Christopher Downs | (Principal Financial and Accounting Officer) |  |
| /s/ Jerzy (George) Gumulka | Director | February 27, 2026 |
| Jerzy (George) Gumulka |  |  |
| /s/ Jeffry R. Keyes | Director | February 27, 2026 |
| Jeffry R. Keyes |  |  |
| /s/ Faith L. Charles | Director | February 27, 2026 |
| Faith L. Charles |  |  |
| /s/ Bettina Cockroft | Director | February 27, 2026 |
| Bettina Cockroft |  |  |
| /s/ Amy Mahery | Director | February 27, 2026 |
| Amy Mahery |  |  |

---

## Ex-5

**Exhibit 5.1**

February 27, 2026

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, Texas 77027

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of the Company's Registration Statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933 (the "Act"), registering 115,032 shares of the Company's common stock, par value $0.001 per share (the "Shares"), issuable pursuant to the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the "2020 Plan").

In rendering this opinion, we have examined: (i) the Amended and Restated Articles of Incorporation and By-laws of the Company, as filed in the Registration Statement; (ii) the Registration Statement; (iii) the 2020 Plan, and (iii) such statutory provisions, certificates and other documents as we have deemed appropriate or necessary as a basis for the opinions hereinafter expressed. We have also examined such other documents and considered such legal matters as we have deemed necessary and relevant as the basis for the opinion set forth below. With respect to such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies, and the authenticity of the originals of those latter documents.

Based upon the foregoing and in reliance thereon, it is our opinion that, as of the date hereof, the Shares to be issued under the 2020 Plan have been duly authorized by all necessary corporate action of the Company, and, upon the issuance and delivery of, and payment for, the Shares in the manner contemplated by the 2020 Plan and assuming the Company completes all actions and proceedings required on its part to be taken prior to the issuance and delivery of the Shares pursuant to the terms of the 2020 Plan, including, without limitation, collection of required payment for the Shares, if applicable, the Shares will be validly issued, fully paid and non-assessable.

This opinion is limited to the Federal law of the United States and Chapter 78 of the Nevada Revised Statutes (including the statutory provisions and all applicable provisions of the Nevada Constitution and the reported judicial cases interpreting those laws currently in effect), and we express no opinion as to the laws of any other jurisdiction. This opinion is rendered pursuant to Item 601(b)(5)(i) of Regulation S-K under the Act. The opinions expressed in this opinion letter are as of the date of this opinion letter only and as to laws covered hereby only as they are in effect on that date, and we assume no obligation to update or supplement such opinions to reflect any facts or circumstances that may come to our attention after that date or any changes in law that may occur or become effective after that date. The opinions herein are limited to the matters expressly set forth in this opinion letter, and no opinion or representation is given or may be inferred beyond the opinions expressly set forth in this opinion letter.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference made to this firm in the Registration Statement under the heading "Interests of Named Experts and Counsel" in the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

Very truly yours,

/s/ ArentFox Schiff LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 31, 2025 with respect to the audited financial statements of CNS Pharmaceuticals, Inc. for the years ended December 31, 2024 and 2023.

*/s/ MaloneBailey, LLP*

www.malonebailey.com

Houston, Texas

February 27, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**CNS Pharmaceuticals, Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, $0.001 par value | (1) | Other | 115032 | $3.04 | $349697.28 | 0.0001381 | $48.30 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $349697.28 |  | 48.30 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $48.30 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers any additional shares of common stock of CNS Pharmaceuticals, Inc. (the "Registrant") that may be granted under the CNS Pharmaceuticals, Inc. 2020 Equity Plan, as amended and restated (the "2020 Plan") to prevent dilution resulting from stock splits, stock dividends or similar transactions. Represents 115,032 shares of Registrant's common stock that were added to the shares reserved for issuance under the 2020 Plan. Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h)) of the Securities Act of 1933, as amended, and based on $3.04 per share, the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Capital Market on February 24, 2026. The Registrant does not have any fee offsets.